Skip to main content
Eric Jacobsen, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

EricDavidJacobsenMD

Oncology Boston, MA

Assistant Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Dr. Jacobsen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jacobsen's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
  • Uconn School Of Medicine
    Uconn School Of MedicineClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NH State Medical License
    NH State Medical License 2023 - 2025
  • MA State Medical License
    MA State Medical License 2003 - 2024

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
    Eric D Jacobsen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
    Eric D Jacobsen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
    Eric D Jacobsen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • More Than 110 Dana-Farber Affiliated Faculty Named as 2021 Top Doctors in Boston Magazine
    More Than 110 Dana-Farber Affiliated Faculty Named as 2021 Top Doctors in Boston MagazineJanuary 5th, 2021
  • Dana-Farber & Other Sites Spur New Wave of Clinical Trials of Therapies for T-cell Lymphoma
    Dana-Farber & Other Sites Spur New Wave of Clinical Trials of Therapies for T-cell LymphomaNovember 14th, 2019
  • Experimental Cancer Shot Shows Promise in Human Lymphoma Patients
    Experimental Cancer Shot Shows Promise in Human Lymphoma PatientsApril 9th, 2019
  • Join now to see all

Hospital Affiliations